| Followers | 48 |
| Posts | 23614 |
| Boards Moderated | 0 |
| Alias Born | 09/16/2012 |
Saturday, July 20, 2024 3:10:03 PM
And, of course, we know that Dr. Mullholand is working on his own therapy and trials that is not DCVAX.
>>Looking beyond this trial, Dr Mulholland continued: “Now that we have recruited the 119 patients to the IPI-GLIO trial we have planned a programme of trials so this work can continue. We have established a Glioblastoma Research Group and laboratory at UCL Cancer Institute. We are bringing together the newest drugs from the pharmaceutical industry together with the latest developments in scientific research to try to find a cure for this devastating disease.”
https://www.ucl.ac.uk/news/2021/jul/brain-cancer-trial-recruits-largest-ever-number-patients
>>A push on getting patients into clinical trials, and more training for young doctors in the disease, the most common form of brain tumour, could pay rapid dividends, he says.
>>There have been few advances in care in decades because patients are being “neglected” by the medical establishment and pharmaceutical industry, Mulholland says bluntly.
The number of patients with glioblastoma, which he sees as an “absolute epidemic, shocking epidemic”, is nonetheless “not enough for a business case” to encourage companies to test their new drugs against the cancer.
https://www.thetimes.com/uk/healthcare/article/brain-cancer-that-affects-3-200-patients-a-year-could-be-cured-with-trials-6dz5sf5l5
>>Looking beyond this trial, Dr Mulholland continued: “Now that we have recruited the 119 patients to the IPI-GLIO trial we have planned a programme of trials so this work can continue. We have established a Glioblastoma Research Group and laboratory at UCL Cancer Institute. We are bringing together the newest drugs from the pharmaceutical industry together with the latest developments in scientific research to try to find a cure for this devastating disease.”
https://www.ucl.ac.uk/news/2021/jul/brain-cancer-trial-recruits-largest-ever-number-patients
>>A push on getting patients into clinical trials, and more training for young doctors in the disease, the most common form of brain tumour, could pay rapid dividends, he says.
>>There have been few advances in care in decades because patients are being “neglected” by the medical establishment and pharmaceutical industry, Mulholland says bluntly.
The number of patients with glioblastoma, which he sees as an “absolute epidemic, shocking epidemic”, is nonetheless “not enough for a business case” to encourage companies to test their new drugs against the cancer.
https://www.thetimes.com/uk/healthcare/article/brain-cancer-that-affects-3-200-patients-a-year-could-be-cured-with-trials-6dz5sf5l5
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
